Trial Profile
Outcomes in patients with Type 2 Diabetes Mellitus treated with Dapagliflozin versus dipeptidyl peptidase-4 inhibitor or a sulfonylurea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association